drugset
drugset / Trial / NCT01471197

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

NCT01471197 ↗

Phase 2 Terminated 9 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.

Timeline

Start
2012-07
Primary completion
2013-02
Completion
2013-02

Outcome

Outcome not reported

Stopped: “Administrative reasons”

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 10 mg/kg Intravenous
Comparator Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma